Trial Profile
Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2024
Price :
$35
*
At a glance
- Drugs Gedatolisib (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Lung cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 02 Feb 2024 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 02 Feb 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jan 2025.
- 09 Jan 2023 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.